Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of September 29, 2026, CTOR trades at $1.01 with a market cap of $108.93M and a P/E ratio of -2.23. CTOR moved +1.94% today. Year to date, CTOR is +5.00%; over the trailing twelve months it is -48.28%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CTOR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.01 |
| Market Cap | $108.93M |
| P/E Ratio | -2.23 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.19 |
| 52-Week Low | $0.49 |
| Volume | 183.62K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.11M |
| Net Income | $-46.06M |
| Gross Margin | 0.00% |
1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.